CytomX Therapeutics to Present at Upcoming February Conferences
Rhea-AI Summary
CytomX Therapeutics (Nasdaq: CTMX) announced management will present at two investor conferences in February 2026: Guggenheim Emerging Outlook: Biotech Summit on Feb 11, 2026 (fireside chat at 4:30 p.m. ET) and World ADC London on Feb 25, 2026 (presentation at 5:00 p.m. GMT).
Investors can find schedules and webcast details on the company's Events and Presentations page.
Positive
- None.
Negative
- None.
News Market Reaction – CTMX
In the Feb 4 session, CTMX declined 6.59%, reflecting a notable negative market reaction. Argus tracked a trough of -13.1% from its starting point during tracking. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jan 08 | Business update | Positive | -0.9% | Outlined 2026 milestones for CX-2051 and CX-801 pipeline programs. |
| Nov 25 | Investor conferences | Neutral | +4.5% | Announced December 2025 presentations at major healthcare investor conferences. |
| Nov 13 | Investor conference | Neutral | -8.8% | Jefferies London fireside chat and investor meetings disclosure. |
| Nov 06 | Earnings update | Neutral | -0.5% | Reported Q3 2025 financials and reiterated CX-2051 and CX-801 progress. |
| Nov 04 | Clinical data | Positive | +4.1% | Presented CX-801 Phase 1 biomarker data supporting ongoing combination study. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Conference and data-related announcements have often aligned with market reactions, while a recent broader business update saw a contrary, negative move.
Over the last few months, CytomX has mixed operational updates with frequent conference participation. A Nov 4, 2025 SITC biomarker update for CX-801 coincided with a positive move, while the Nov 6, 2025 Q3 earnings/business update saw only a slight decline. Subsequent December and November 2025 conference appearances produced both gains and losses. The Jan 8, 2026 2026 business and clinical milestone update was followed by a small drop, showing occasional divergence between seemingly constructive news and near-term price action.
Key Terms
biologics medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that management will participate in the following conferences in February.
Guggenheim Emerging Outlook: Biotech Summit 2026
Date: Wednesday, February 11, 2026
Fireside Chat: 4:30 p.m. ET
Location: New York, NY
World ADC London 2026
Date: Wednesday, February 25, 2026
Presentation: 5:00 p.m. GMT
Location: London, UK
Additional information can be found on the Events and Presentations page of CytomX’s website at www.cytomx.com.
About CytomX Therapeutics, Inc.
CytomX is a clinical-stage, oncology-focused biopharmaceutical company focused on developing novel conditionally activated, masked biologics designed to be localized to the tumor microenvironment. By pioneering a novel pipeline of localized biologics, powered by its PROBODY® therapeutic platform, CytomX’s vision is to create safer, more effective therapies for the treatment of cancer. CytomX’s robust and differentiated pipeline comprises therapeutic candidates across multiple treatment modalities including antibody-drug conjugates (“ADCs”), T-cell engagers, and immune modulators such as cytokines. CytomX’s clinical-stage pipeline includes varsetatug masetecan (formerly CX-2051) and CX-801. Varseta-M is a masked, conditionally activated ADC directed toward epithelial cell adhesion molecule (EpCAM), armed with a topoisomerase-1 inhibitor payload and was discovered in collaboration with ImmunoGen, now part of AbbVie. EpCAM is a highly expressed but previously undruggable tumor antigen due to expression on normal tissues. Varseta-M is designed to open a therapeutic window for this high potential target and deliver meaningful anti-cancer activity in solid tumors, including CRC. CX-801 is a masked interferon alpha-2b PROBODY® cytokine with broad potential applicability in traditionally immuno-oncology sensitive as well as insensitive (cold) tumors. CytomX has established strategic collaborations with multiple leaders in oncology, including Amgen, Astellas, Bristol Myers Squibb, Regeneron and Moderna. For more information about CytomX and how it is working to make conditionally activated treatments the new standard-of-care in the fight against cancer, visit www.cytomx.com and follow us on LinkedIn and X (formerly Twitter).
Company Contact:
Chris Ogden
SVP, Chief Financial Officer
cogden@cytomx.com
Investor Contact:
Precision AQ (formerly Stern Investor Relations)
Stephanie Ascher
stephanie.ascher@precisionaq.com
Media Contact:
Precision AQ
Colleen Ketchum
colleen.ketchum@precisionaq.com
